ALERT: Your health is top priority. We’re committed to providing reliable COVID-19 resources to keep you informed and safe.

Study Links Popular Heartburn Drugs to Esophageal Cancer


Editors carefully fact-check all Drugwatch content for accuracy and quality.

Drugwatch has a stringent fact-checking process. It starts with our strict sourcing guidelines.

We only gather information from credible sources. This includes peer-reviewed medical journals, reputable media outlets, government reports, court records and interviews with qualified experts.

Doctor observing esophagus

Popular heartburn drugs prescribed to prevent esophageal cancer may actually cause the disease, according to a new study in Cancer Epidemiology. The drugs include familiar names such as Prilosec, Nexium and Prevacid. They are part of a class of drugs called proton pump inhibitors.

The American Gastroenterological Association recommends prescribing PPIs for all Barrett’s esophagus patients. Long-term reflux causes the condition. People with Barrett’s esophagus face a higher risk of developing esophageal cancer.

Largest Ever PPI, Esophageal Cancer Study

The Swedish study was the largest ever conducted on PPI use and esophageal cancer. It found PPI use may be responsible for more than 5 percent of esophageal cancer cases in Sweden. Researchers looked at medical records for more than 796,000 patients. This included every Swedish adult given PPI maintenance therapy between 2005 and 2012.

Researchers compared those taking PPIs to the general population. They looked at cancer rates for both groups. Esophageal cancer remained rare in both groups. But the risk was higher for those taking PPIs.

Are you suffering from complications after taking a PPI? Get a Free Case Review

They concluded long-term PPI use is associated with increased esophageal cancer risk.

“Long term use of PPIs should be addressed with caution,” the researchers wrote.

They said their findings may cause doctors to re-evaluate PPI treatments.

Critics Question PPI Study’s Results

There has been a dramatic increase in esophageal cancer cases since the first PPI hit the market in 1988. The rates increased six-fold between 1975 and 2001 before slowing. But critics claim this study does not make a solid connection between PPI use and cancer.

“This study demonstrates an association, not a cause and effect. I would be very careful not to state that PPIs cause esophageal cancer based on these data,” Dr. Scott Gabbard of the Cleveland Clinic told Medscape.

Other critics claim the study fails to account for other potential causes. It does not factor in smoking, alcohol use or obesity.

Earlier Research Questioned PPI Cancer Prevention, Found Cancer Risks

A 2011 study also found an increased cancer risk. University of Pittsburgh School of Medicine researchers looked at patients taking PPIs to control reflux symptoms. They said long-term PPI use posed “significantly higher odds” of esophageal cancer. The study appeared in the journal Archives of Surgery.

More recently, a 2017 study found PPIs did not prevent esophageal cancer. Another study has found PPI use can double the risk for gastric cancer in some patients.

A PLoS One review looked at results from nine earlier studies. They included 5,700 Barrett’s esophagus patients. Researchers found no evidence PPIs prevented esophageal cancer. They said doctors should reconsider prescribing PPIs to prevent cancer. And that they should be aware it “has not been proven with statistical significance.”

Another 2017 study in Gut warned of other cancer risks with PPI use. Researchers found some patients’ gastric cancer risk doubled with long-term PPI use. That study looked at patients treated for Helicobacter pylori infections. The study examined more 63,000 patients. It found the risk increased the longer people took PPIs.

Terry Turner
Written By Terry Turner Writer

Terry Turner has been writing articles and producing news broadcasts for more than 25 years. He covers FDA policy, proton pump inhibitors, and medical devices such as hernia mesh, IVC filters, and hip and knee implants. An Emmy-winning journalist, he has reported on health and medical policy issues before Congress, the FDA and other federal agencies. Some of his qualifications include:

  • American Medical Writers Association (AMWA) and The Alliance of Professional Health Advocates member
  • Centers for Disease Control and Prevention Health Literacy certificates
  • Original works published or cited in Washington Examiner, MedPage Today and The New York Times
  • Appeared as an expert panelist on hernia mesh lawsuits on the BBC
Edited By

8 Cited Research Articles writers follow rigorous sourcing guidelines and cite only trustworthy sources of information, including peer-reviewed journals, court records, academic organizations, highly regarded nonprofit organizations, government reports and interviews with qualified experts. Review our editorial policy to learn more about our process for producing accurate, current and balanced content.

  1. Brusselaers, N., Engstrand, L. and Lagergren, J. (2018, February 22). Maintenance Proton Pump Inhibition Therapy and Risk of Oesophageal Cancer. Cancer Epidemiology. Retrieved from
  2. Jenkins, K. (2018, March 5). Long-Term PPI Use and Increased Esophageal CA Risk. Medscape. Retrieved from
  3. American Cancer Society. (2017, June 14). Can Esophageal Cancer Be Prevented? Retrieved from
  4. Hu, Q., et al. (2017, January 10). Proton Pump Inhibitors Do Not reduce the Risk of Esophageal Adenocarcinoma in Patients with Barrett’s Esophagus: A Systematic Review and Meta-Analysis. PLoS One. Retrieved from
  5. Cheung, K.S., et al. (2017, October 31). Long-Term Proton Pump Inhibitors and Risk of Gastric Cancer Development After Treatment for Helicobacter pylori: A Population-Based Study. Gut (BMJ Journals). Retrieved from
  6. Nason, K.S., et al. (2011, July). Gastroesophageal Reflux Disease Symptom Severity, Proton Pump Inhibitor Use, and Esophageal Carcinogenesis. Archives of Surgery. Retrieved from
  7. Templeton, D. (2011, August 4). Popular Heartburn Drugs May Increase Esophageal Cancer Risk. The Seattle Times. Retrieved from
  8. Thrift, A.P. and Whiteman, D.C. (2012, December 1). The Incidence of Esophageal Adenocarcinoma Continues to Rise: Analysis of Period and Birth Cohort Effects on Recent Trends. Annals of Oncology. Retrieved from
View All Sources
Call to speak with a legal expert
Who Am I Calling?

Calling this number connects you with one of Drugwatch's trusted legal partners. A law firm representative will review your case for free.

Drugwatch's sponsors support the organization’s mission to keep people safe from dangerous drugs and medical devices. For more information, visit our sponsors page.

(866) 587-0279